Malaysia Pharma and Healthcare Sector Report 2026-2027

Malaysia's pharmaceutical and healthcare sector ranks among the most sophisticated in Southeast Asia. Malaysia's healthcare system is segmented into a publicly funded, government-operated sector and a fee-paying private sector. The public healthcare system, managed by the Ministry of Health (MoH), is the foundation of Malaysia's healthcare infrastructure. It provides heavily subsidised healthcare services to Malaysian citizens. Within the public healthcare system, patients are granted access to higher-level services only after consultations with general practitioners or outpatient divisions, indicating that their treatment necessitates more specialised expertise or advanced technology. Private healthcare providers enable fee-paying patients to consult specialists directly, thereby expediting treatment but potentially leading to unnecessary testing and treatments.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for Malaysia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in Malaysia
• Crystallise the forces both driving and restraining this sector in Malaysia
• Ascertain Malaysia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Malaysia.
• Build a clear picture of trends, output and consumption for specific sub-sectors